Targeting ALK - From Discovery to Frontline Treatment

In this 'keynote', Dr. Yael Mosse presents on the discovery of ALK aberrations in neuroblastoma, their significance at diagnosis and at relapse, drug development strategies and plans to incorporate ALK inhibitors into frontline therapy with potential joint COG and SIOPEN studies, and germline ALK mutation.
This is a recorded presentation from the 2020 symposium.